

Press Releases

Boston Scientific Renews Agreement with Lumenis® to Deliver Innovative Laser Products to Treat Urologic Conditions

Mar 8, 2012

NATICK, Mass., March 8, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) and Lumenis, the market leader in holmium laser technology, announced the signing of a five-year contract extending the existing commercial agreement between the two companies and promoting continued investments in laser and fiber product development for urologic applications. Under the agreement, Boston Scientific will continue as the exclusive U.S. distributor for Lumenis Holmium Laser Fibers, designed for use with surgical lasers to treat a variety of urologic conditions.

"Lumenis is excited to continue its long-time distribution agreement with Boston Scientific, a leader in minimally invasive solutions for the urology market," said Bob Di Silvio, Senior Vice President and President, Lumenis Americas. "Together, we offer urologists and their patients a comprehensive set of cost-effective solutions delivered by highly experienced and knowledgeable sales teams."

"We are pleased to renew our alliance with Lumenis, which has been very successful in strengthening our product offerings in this important market," said Michael Phalen, Executive Vice President and President of the MedSurg Division at Boston Scientific. "We look forward to continuing to provide urologists with clinically beneficial technologies that improve patient care."

About Boston Scientific

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties. For more information, please visit:

www.bostonscientific.com.

About Lumenis

Lumenis, the world's largest medical laser company, is a global developer, manufacturer and distributor of laser and light-based devices for surgical, ophthalmic and aesthetic applications, with more than 800 employees worldwide. For more information about Lumenis and its products, please visit: www.lumenis.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding product performance, clinical outcomes and our agreements with Lumenis. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – *Risk Factors* in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we

may update in Part II, Item 1A – *Risk Factors* in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

CONTACT: Eric Olson

336-293-4393 (office)

Media Relations

Boston Scientific Corporation

eric.olson@bsci.com

Sean Findlen

617-520-7268 (office)

Media Relations

Weber Shandwick

sfindlen@webershandwick.com

Sean Wirtjes

508-652-5305 (office)

Investor Relations

Boston Scientific Corporation

investor_relations@bsci.com

SOURCE Boston Scientific Corporation